Montelukast Suppresses the Development of Irritable Bowel Syndrome Phenotype Possibly Through Modulating Nf-Κb Signaling in an Experimental Model

Montelukast Suppresses the Development of Irritable Bowel Syndrome Phenotype Possibly Through Modulating Nf-Κb Signaling in an Experimental Model Publisher Pubmed

Khodabakhsh P¹ ; Khoie N² ; Dehpour AR^{2, 3} ; Abdollahi A⁴ ; Ghazikhansari M² ; Shafaroodi H^{2, 3}

Show Affiliations

1. Student Research Committee, Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3. Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Pathology, School of Medicine, IKHC, Teheran University of Medical Sciences, Tehran, Iran

Source: Inflammopharmacology Published:2022

Abstract

Irritable bowel syndrome (IBS) is a functional gut disorder with multi-factorial pathophysiology that causes recurring pain or discomfort in the abdomen, as well as altered bowel habits. Montelukast, a well-known cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, is widely used for the anti-inflammatory management of asthma. The present study aimed to evaluate the effects of pharmacological inhibition of CysLT1R on acetic acid-induced diarrhea-predominant IBS (D-IBS) in rats. Behavioral pain responses to noxious mechanical stimulation were decreased in the montelukast-treated rats as compared to the model animals following colorectal distension (CRD)-induced visceral hypersensitivity. Stool frequency decreased dose-dependently by montelukast in IBS rats exposed to restraint stress. A significantly shorter immobility time was also observed in IBS rats who received montelukast vs IBS group in the forced swimming test (depression-like behavior). Furthermore, there were significant decreases in the NF-κB protein expression, inflammatory cytokine (TNF-α, and IL-1ß) levels, and histopathological inflammatory injuries concomitant with increased anti-inflammatory cytokine, IL-10, in montelukast-treated rats compared with the IBS group. Cysteinyl leukotriene production and CysLT1R mRNA expression showed no remarkable differences among the experimental groups. The present results suggest the possible beneficial effects of montelukast in the management of D-IBS symptoms. The molecular mechanism underlying such effects, at least to some extent, might be through modulating CysLT1R-mediated NF-κB signaling. Yet, more studies are required to demonstrate the clinical potential of this drug for IBS therapy. © 2022, The Author(s), under exclusive licence to Springer Nature Switzerland AG.

2. The Association Between Dietary Total Antioxidant Capacity and Odds and Severity of Irritable Bowel Syndrome Among Iranian Adults: A Cross-Sectional Study, BMC Gastroenterology (2022)

3. Hippocampal Neuroprotection Mediated by Secretome of Human Mesenchymal Stem Cells Against Experimental Stroke, CNS Neuroscience and Therapeutics (2022)

4. The Reality of Modeling Irritable Bowel Syndrome: Progress and Challenges, Expert Opinion on Drug Discovery (2025)

5. Effect of Metformin on Epidermal Neural Crest Stem Cells and Their Potential Application in Ameliorating Paclitaxel-Induced Neurotoxicity Phenotype, Stem Cell Reviews and Reports (2024)

Experts (# of related papers)

View all Related Experts

Mohammad Abdollahi (2)

Shekoufeh Nikfar (1)

Style	Citing Format
MLA	Khodabakhsh P, et al.. "Montelukast Suppresses the Development of Irritable Bowel Syndrome Phenotype Possibly Through Modulating Nf-Κb Signaling in an Experimental Model." Inflammopharmacology, vol. 30, no. 1, 2022, pp. 313-325.
APA	Khodabakhsh P, Khoie N, Dehpour AR, Abdollahi A, Ghazikhansari M, Shafaroodi H (2022). Montelukast Suppresses the Development of Irritable Bowel Syndrome Phenotype Possibly Through Modulating Nf-Κb Signaling in an Experimental Model. Inflammopharmacology, 30(1), 313-325.
Chicago	Khodabakhsh P, Khoie N, Dehpour AR, Abdollahi A, Ghazikhansari M, Shafaroodi H. "Montelukast Suppresses the Development of Irritable Bowel Syndrome Phenotype Possibly Through Modulating Nf-Κb Signaling in an Experimental Model." Inflammopharmacology 30, no. 1 (2022): 313-325.
Harvard	Khodabakhsh P et al. (2022) 'Montelukast Suppresses the Development of Irritable Bowel Syndrome Phenotype Possibly Through Modulating Nf-Κb Signaling in an Experimental Model', Inflammopharmacology, 30(1), pp. 313-325.
Vancouver	Khodabakhsh P, Khoie N, Dehpour AR, Abdollahi A, Ghazikhansari M, Shafaroodi H. Montelukast Suppresses the Development of Irritable Bowel Syndrome Phenotype Possibly Through Modulating Nf-Κb Signaling in an Experimental Model. Inflammopharmacology. 2022;30(1):313-325.
BibTex	@article{ author = {Khodabakhsh P and Khoie N and Dehpour AR and Abdollahi A and Ghazikhansari M and Shafaroodi H}, title = {Montelukast Suppresses the Development of Irritable Bowel Syndrome Phenotype Possibly Through Modulating Nf-Κb Signaling in an Experimental Model}, journal = {Inflammopharmacology}, volume = {30}, number = {1}, pages = {313-325}, year = {2022} }
RIS	TY - JOUR AU - Khodabakhsh P AU - Khoie N AU - Dehpour AR AU - Abdollahi A AU - Ghazikhansari M AU - Shafaroodi H TI - Montelukast Suppresses the Development of Irritable Bowel Syndrome Phenotype Possibly Through Modulating Nf-Κb Signaling in an Experimental Model JO - Inflammopharmacology VL - 30 IS - 1 SP - 313 EP - 325 PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract